495 results on '"Endris, Volker"'
Search Results
2. Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
3. A “Two-in-One Hit” Model of Shortcut Carcinogenesis in MLH1 Lynch Syndrome Carriers
4. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
5. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
6. Varianteninterpretation in der molekularen Pathologie und Onkologie: Eine Einführung
7. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
8. Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors
9. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts
10. Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases
11. Molecular dissection of large cell carcinomas of the lung with null immunophenotype
12. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas
13. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study
14. The BRCA2 mutation status shapes the immune phenotype of prostate cancer
15. The majority of β-catenin mutations in colorectal cancer is homozygous
16. Correction to: The majority of β-catenin mutations in colorectal cancer is homozygous
17. The Novel Rho-GTPase Activating Gene MEGAP/srGAP3 Has a Putative Role in Severe Mental Retardation
18. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas
19. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
20. Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie
21. Supplementary Patient Data from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
22. Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
23. Supplementary Table S1 from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
24. Supplementary Tables S1-S7 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
25. Data from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
26. Supplementary Figure S2 from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
27. Supplementary Figures S1-S10 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
28. Supplementary Methods from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
29. A “two-in-one hit” model of shortcut carcinogenesis in MLH1 Lynch syndrome carriers
30. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene
31. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
32. BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
33. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial
34. Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data
35. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial
36. Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas
37. Precision oncology based on omics data: The NCT Heidelberg experience
38. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector™
39. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
40. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer
41. Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary
42. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine
43. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis
44. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
45. Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance
46. Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer
47. Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies
48. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.
49. Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
50. KRAS/GNAS‐testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound‐guided workup of suspected mucinous neoplasms of the pancreas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.